Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Alzheimer's Disease

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Alzheimer s Disease

In brief

This study is grounded in the regulatory mechanisms of the glymphatic system and applies repetitive transcranial magnetic stimulation (rTMS) to the treatment of Alzheimer's disease (AD). The clinical efficacy and safety of rTMS will be systematically evaluated. Furthermore, transcranial magnetic stimulation-evoked potentials (TMS-EEG) and functional near-infrared spectroscopy (fNIRS) will be employed to investigate, from the perspectives of synaptic plasticity and neurovascular coupling, the mechanisms by which rTMS influences glymphatic function. Collectively, this work aims to provide new insights into both the therapeutic effectiveness and the underlying mechanisms of rTMS in AD.

Key facts

Study ID

NCT07324161

Run by

Fujian Medical University Union Hospital

People needed

66

Starts

2025-04-16

Expected to finish

2029-04-30

Last updated by the study team

2026-01-14

Who can join

Age: 50 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Meets the 2018 NIA-AA diagnostic criteria for Alzheimer's disease (AD)
• Meets DSM-5 diagnostic criteria
• Mild to moderate disease severity (CDR Global Score 1 to 2)
• Evidence of AD pathology: positive amyloid PET OR positive cerebrospinal fluid (CSF) AD biomarkers OR positive plasma AD biomarkers

You may not qualify if…

• Contraindications to rTMS treatment
• Severe complications or immune diseases
• Unable to cooperate with study procedures
• History of epilepsy

Where it is running

• rTMS — Fuzhou, Fujian, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.